Spermosens AB engages in the research and development of medical device for diagnosing male infertility. It develops a chip that employs sperm-specific receptor proteins of oocyte-origin that binds and induces a biochemical response. The response is then analyzed and determines the viability of the sperm. The company was founded by Kushagr Punyanis and Sudha Srivastavas on October 18, 2018 and is headquartered in Lund, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company